• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Analysis of the initial lot of the CDC 2019-Novel Coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel

tetano

Editor, Senior Moderator
PLoS One


. 2021 Dec 15;16(12):e0260487.
doi: 10.1371/journal.pone.0260487. eCollection 2021.
Analysis of the initial lot of the CDC 2019-Novel Coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel


Justin S Lee[SUP] 1 [/SUP], Jason M Goldstein[SUP] 1 [/SUP], Jonathan L Moon[SUP] 1 [/SUP], Owen Herzegh[SUP] 1 [/SUP], Dennis A Bagarozzi Jr[SUP] 1 [/SUP], M Steven Oberste[SUP] 2 [/SUP], Heather Hughes[SUP] 1 [/SUP], Kanwar Bedi[SUP] 1 [/SUP], Dorothie Gerard[SUP] 1 [/SUP], Brenique Cameron[SUP] 1 [/SUP], Christopher Benton[SUP] 1 [/SUP], Asiya Chida[SUP] 1 [/SUP], Ausaf Ahmad[SUP] 1 [/SUP], David J Petway Jr[SUP] 1 [/SUP], Xiaoling Tang[SUP] 1 [/SUP], Nicky Sulaiman[SUP] 1 [/SUP], Dawit Teklu[SUP] 1 [/SUP], Dhwani Batra[SUP] 1 [/SUP], Dakota Howard[SUP] 1 [/SUP], Mili Sheth[SUP] 1 [/SUP], Wendi Kuhnert[SUP] 3 [/SUP], Stephanie R Bialek[SUP] 2 [/SUP], Christina L Hutson[SUP] 4 [/SUP], Jan Pohl[SUP] 1 [/SUP], Darin S Carroll[SUP] 1 [/SUP]



Affiliations

Abstract

At the start of the COVID-19 pandemic, the Centers for Disease Control and Prevention (CDC) designed, manufactured, and distributed the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel for SARS-CoV-2 detection. The diagnostic panel targeted three viral nucleocapsid gene loci (N1, N2, and N3 primers and probes) to maximize sensitivity and to provide redundancy for virus detection if mutations occurred. After the first distribution of the diagnostic panel, state public health laboratories reported fluorescent signal in the absence of viral template (false-positive reactivity) for the N3 component and to a lesser extent for N1. This report describes the findings of an internal investigation conducted by the CDC to identify the cause(s) of the N1 and N3 false-positive reactivity. For N1, results demonstrate that contamination with a synthetic template, that occurred while the "bulk" manufactured materials were located in a research lab for quality assessment, was the cause of false reactivity in the first lot. Base pairing between the 3' end of the N3 probe and the 3' end of the N3 reverse primer led to amplification of duplex and larger molecules resulting in false reactivity in the N3 assay component. We conclude that flaws in both assay design and handling of the "bulk" material, caused the problems with the first lot of the 2019-nCoV Real-Time RT-PCR Diagnostic Panel. In addition, within this study, we found that the age of the examined diagnostic panel reagents increases the frequency of false positive results for N3. We discuss these findings in the context of improvements to quality control, quality assurance, and assay validation practices that have since been improved at the CDC.
 
Back
Top Bottom